Relenza (Zanamivir) News and Research

RSS

Relenza (zanamivir) is an anti-viral drug, for persons aged 7 years and older for the treatment of uncomplicated influenza illness. This product is approved to treat type A and B influenza, the two types most responsible for flu epidemics. Clinical studies showed that for the drug to be effective, patients needed to start treatment within two days of the onset of symptoms. The drug seemed to be less effective in patients whose symptoms weren't severe or didn't include a fever. Relenza is approved for preventive use, to decrease the risk of developing influenza illness, for persons aged 5 and older. Relenza is a powder that is inhaled twice a day for five days from a breath-activated plastic device called a Diskhaler for treatment of influenza. For preventive use to reduce the risk of getting influenza, Relenza is inhaled once daily for 10 to 28 days as prescribed by a healthcare provider.

WHO warns Aussies to prepare for deadly flu

The World Health Organisation (WHO) is warning Australians to prepare for a potentially deadly flu season.

23 Mar 2008

Amantadine and rimantadine for influenza A in children and the elderly

The antiviral drug amantadine can prevent some cases of influenza in children, and the related medication rimantadine can reduce fever in youngsters who have the flu, according to a new review of evidence.

8 Feb 2008

Brits gear up for pandemic while FDA warns about flu jabs side-effects

The British government says it plans to double its stockpile of antiviral drugs such as Tamiflu to cope with the possibility of a flu pandemic.

26 Nov 2007

Biota increases damages claim against GlaxoSmithKline

Australian company Biota has filed its updated Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support the influenza drug, Relenza, discovered by Biota and licensed to GSK in 1990.

31 Jul 2007

HHS and BioCryst advance development of new influenza drug

HHS Secretary Mike Leavitt announced that the Department has awarded a $102.6 million, four-year contract to BioCryst Pharmaceuticals, Inc. for advanced development of their influenza antiviral drug, peramivir.

7 Jan 2007

New bird flu drug will provide new line of defence

Flu experts say a new flu drug with the ability to kill deadly strains of bird flu promises to provide a much needed third option should a pandemic occur.

28 Nov 2006

Experts say Britain vulnerable to bird flu pandemic

Experts in Britain believe the government should have stockpiled more than one antiviral drug in order to tackle a bird flu pandemic and say Britain has been left vulnerable because the stockpile of anti virus drugs is deficient.

20 Nov 2006

Chink in the armour of H5N1 bird flu virus

British scientists say they have made a breakthrough in their development of a bird flu drug that could treat humans in the event of an outbreak.

20 Aug 2006

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

A class of drugs commonly used to treat typical influenza symptoms such as fever, headache and cough do not prevent people from becoming infected with the flu virus.

19 Jul 2006

Brits to trial bird flu vaccine on humans

The British drug company PowderMed has applied for permission to conduct the first trial in Britain of a vaccine against the avian flu virus.

10 Jul 2006

Renewed interest in studying influenza A viruses

The emergence of the avian influenza virus H5N1 that is currently devastating chicken flocks in many countries and threatening to unleash a worldwide epidemic among humans has triggered a renewed interest among scientists in studying influenza A viruses, according to investigators at St. Jude Children's Research Hospital.

9 May 2006

GlaxoSmithKline announces start of clinical trials to test two pandemic vaccines against the H5N1

GlaxoSmithKline has announced the start of an international clinical trial program to test two pandemic vaccines against the H5N1 strain of the avian influenza virus in humans. This dual approach reflects the company's commitment to provide health authorities with concrete options to face the threat of a pandemic.

30 Mar 2006

U.S. buys more Relenza and Tamiflu for future influenza pandemics

The United States Department of Health and Human Services has announced additional purchases of antiviral drugs that could be used in the event of a potential influenza pandemic.

23 Mar 2006

Two drug giants team up to develop new bird flu therapy

Two major drug companies have teamed up in order to develop a treatment for pandemic flu strains.

22 Feb 2006

Tamiflu alone won't work in bird flu pandemic

In a review published this week a warning has been issued against the apparent reliance by most countries on the drug Tamiflu to combat a bird flu pandemic.

19 Jan 2006

Experts demand more funds to stop the spread of bird flu

At a meeting in Beijing to whip up funds for the global fight against bird flu, the European Union has raised its contribution to the fund by $20 million taking their total commitment to $120 million, but other contributions appear to be thin on the ground.

18 Jan 2006